Download PDF
Semin Thromb Hemost 2013; 39(04): 373-381
DOI: 10.1055/s-0033-1334486
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Plasminogen–Plasmin System in the Pathogenesis and Treatment of Lung and Pleural Injury

Torry Tucker
1   Department of Cellular and Molecular Biology, The Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas
,
Steven Idell
1   Department of Cellular and Molecular Biology, The Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
16 March 2013 (online)

    Permissions and Reprints

Abstract

Lung and pleural injuries are characterized by inflammation, fibrinous transitional matrix deposition, and ultimate scarification. The accumulation of extravascular fibrin is due to concurrently increased local coagulation and decreased fibrinolysis, the latter mainly as a result of increased plasminogen activator inhibitor-1 (PAI-1) expression. Therapeutic targeting of disordered fibrin turnover has long been used for the treatment of pleural disease. Intrapleural fibrinolytic therapy has been found to be variably effective in clinical trials, which likely reflects empiric dosing that does not account for the wide variation in pleural fluid PAI-1 levels in individual patients. The incidence of empyema is increasing, providing a strong rationale to identify more effective, nonsurgical treatment to improve pleural drainage and patient outcomes. Therapeutics designed to resist inhibition by PAI-1 are in development for the treatment of pleural loculation and impaired drainage. The efficacy and safety of these strategies remains to be proven in clinical trial testing. Fibrinolytic therapy administered via the airway has also been proposed for the treatment of acute lung injury, but this approach has not been rigorously validated and is not part of routine clinical management at this time. Challenges to airway delivery of fibrinolysins relate to bioavailability, distribution, and dosing of the interventional agents.

Keywords

pleura - lung - injury and fibrinolysis - fibrinolytic therapy - plasminogen activator inhibitor-1
 

  • References

  • 1 Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2 (1) 41-73
    CrossrefPubMedGoogle Scholar
  • 2 Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315 (26) 1650-1659
    CrossrefPubMedGoogle Scholar
  • 3 Ware LB, Bastarache JA, Wang L, Matthay MA. Modulation of intra-alveolar fibrin deposition by the alveolar epithelium in acute lung injury: clinical and experimental evidence. Proc Am Thorac Soc 2008; 5 (3) 358-359
    PubMedGoogle Scholar
  • 4 Bastarache JA. The complex role of fibrin in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2009; 296 (3) L275-L276
    CrossrefPubMedGoogle Scholar
  • 5 Idell S, James KK, Levin EG , et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84 (2) 695-705
    CrossrefPubMedGoogle Scholar
  • 6 Idell S. The pathogenesis of pleural space loculation and fibrosis. Curr Opin Pulm Med 2008; 14 (4) 310-315
    CrossrefPubMedGoogle Scholar
  • 7 Idell S, Mazar AP, Bitterman P, Mohla S, Harabin AL. Fibrin turnover in lung inflammation and neoplasia. Am J Respir Crit Care Med 2001; 163 (2) 578-584
    CrossrefPubMedGoogle Scholar
  • 8 Kim HJ, Ingbar DH, Henke CA. Integrin mediation of type II cell adherence to provisional matrix proteins. Am J Physiol 1996; 271 (2 Pt 1) L277-L286
    PubMedGoogle Scholar
  • 9 Larsson O, Diebold D, Fan D , et al. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS ONE 2008; 3 (9) e3220
    CrossrefPubMedGoogle Scholar
  • 10 Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010; 176 (6) 2626-2637
    CrossrefPubMedGoogle Scholar
  • 11 Polunovsky VA, Rosenwald IB, Tan AT , et al. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996; 16 (11) 6573-6581
    PubMedGoogle Scholar
  • 12 Bertozzi P, Astedt B, Zenzius L , et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. [see comments] N Engl J Med 1990; 322 (13) 890-897
    CrossrefPubMedGoogle Scholar
  • 13 Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261 (4 Pt 1) L240-L248
    PubMedGoogle Scholar
  • 14 Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004; 113 (2) 148-157
    CrossrefPubMedGoogle Scholar
  • 15 Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31 (4, Suppl) S213-S220
    CrossrefPubMedGoogle Scholar
  • 16 Idell S, Gonzalez KK, MacArthur CK , et al. Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis. Am Rev Respir Dis 1987; 136 (1) 124-133
    CrossrefPubMedGoogle Scholar
  • 17 Idell S, Peterson BT, Gonzalez KK , et al. Local abnormalities of coagulation and fibrinolysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury. Am Rev Respir Dis 1988; 138 (5) 1282-1294
    CrossrefPubMedGoogle Scholar
  • 18 Idell S, James KK, Gillies C, Fair DS, Thrall RS. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135 (2) 387-399
    PubMedGoogle Scholar
  • 19 Idell S, Peters J, James KK, Fair DS, Coalson JJ. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Invest 1989; 84 (1) 181-193
    CrossrefPubMedGoogle Scholar
  • 20 Idell S, James KK, Coalson JJ. Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damage: trends in two forms of lung injury. Crit Care Med 1992; 20 (10) 1431-1440
    CrossrefPubMedGoogle Scholar
  • 21 Idell S, Kumar A, Koenig KB, Coalson JJ. Pathways of fibrin turnover in lavage of premature baboons with hyperoxic lung injury. [see comments] Am J Respir Crit Care Med 1994; 149 (3 Pt 1) 767-775
    CrossrefPubMedGoogle Scholar
  • 22 Viscardi RM, Broderick K, Sun CC , et al. Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. Am Rev Respir Dis 1992; 146 (2) 492-499
    CrossrefPubMedGoogle Scholar
  • 23 Midde KK, Batchinsky AI, Cancio LC , et al. Wood bark smoke induces lung and pleural plasminogen activator inhibitor 1 and stabilizes its mRNA in porcine lung cells. Shock 2011; 36 (2) 128-137
    CrossrefPubMedGoogle Scholar
  • 24 Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991; 144 (1) 187-194
    CrossrefPubMedGoogle Scholar
  • 25 Idell S, Zwieb C, Kumar A, Koenig KB, Johnson AR. Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 1992; 7 (4) 414-426
    CrossrefPubMedGoogle Scholar
  • 26 Bajaj MS, Pendurthi U, Koenig K, Pueblitz S, Idell S. Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells. Eur Respir J 2000; 15 (6) 1069-1078
    CrossrefPubMedGoogle Scholar
  • 27 Idell S, Pendurthi U, Pueblitz S, Koenig K, Williams T, Rao LV. Tissue factor pathway inhibitor in tetracycline-induced pleuritis in rabbits. Thromb Haemost 1998; 79 (3) 649-655
    PubMedGoogle Scholar
  • 28 Idell S, Allen T, Chen S, Koenig K, Mazar A, Azghani A. Intrapleural activation, processing, efficacy, and duration of protection of single-chain urokinase in evolving tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2007; 292 (1) L25-L32
    PubMedGoogle Scholar
  • 29 Idell S, Azghani A, Chen S , et al. Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits. Exp Lung Res 2007; 33 (8-9) 419-440
    CrossrefPubMedGoogle Scholar
  • 30 Karandashova S, Florova G, Azghani AO , et al. Intrapleural adenoviral delivery of human PAI-1 exacerbates TCN-induced pleural injury in rabbits. Am J Respir Cell Mol Biol 2013; 48 (1) 44-52
    CrossrefPubMedGoogle Scholar
  • 31 Heffner JE, Klein JS, Hampson C. Interventional management of pleural infections. Chest 2009; 136 (4) 1148-1159
    CrossrefPubMedGoogle Scholar
  • 32 Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006; 3 (1) 75-80
    CrossrefPubMedGoogle Scholar
  • 33 Light RW. Update: management of parapneumonic effusions. Clin Pulm Med 2003; 10 (6) 336-342
    CrossrefPubMedGoogle Scholar
  • 34 Idell S, Kumar A, Zwieb C, Holiday D, Koenig KB, Johnson AR. Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. Am J Physiol 1994; 267 (6 Pt 1) L693-L703
    PubMedGoogle Scholar
  • 35 Bastarache JA, Wang L, Geiser T , et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007; 62 (7) 608-616
    CrossrefPubMedGoogle Scholar
  • 36 Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008; 294 (5) L874-L881
    CrossrefPubMedGoogle Scholar
  • 37 Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007; 36 (4) 497-503
    CrossrefPubMedGoogle Scholar
  • 38 Gross TJ, Simon RH, Kelly CJ, Sitrin RG. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. Am J Physiol 1991; 260 (4 Pt 1) L286-L295
    PubMedGoogle Scholar
  • 39 Gross TJ, Simon RH, Sitrin RG. Tissue factor procoagulant expression by rat alveolar epithelial cells. Am J Respir Cell Mol Biol 1992; 6 (4) 397-403
    CrossrefPubMedGoogle Scholar
  • 40 Simon RH, Gross TJ, Edwards JA, Sitrin RG. Fibrin degradation by rat pulmonary alveolar epithelial cells. Am J Physiol 1992; 262 (4 Pt 1) L482-L488
    PubMedGoogle Scholar
  • 41 Sitrin RG, Todd III RF, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97 (8) 1942-1951
    CrossrefPubMedGoogle Scholar
  • 42 Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93 (4) 1380-1387
    CrossrefPubMedGoogle Scholar
  • 43 Chapman HA, Stahl M, Allen CL, Yee R, Fair DS. Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Respir Dis 1988; 137 (6) 1417-1425
    CrossrefPubMedGoogle Scholar
  • 44 Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9 (5) 714-724
    CrossrefPubMedGoogle Scholar
  • 45 Reilly JJ, Chapman Jr HA. Association between alveolar macrophage plasminogen activator activity and indices of lung function in young cigarette smokers. Am Rev Respir Dis 1988; 138 (6) 1422-1428
    CrossrefPubMedGoogle Scholar
  • 46 Shetty S, Idell S. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J Biol Chem 2001; 276 (27) 24549-24556
    CrossrefPubMedGoogle Scholar
  • 47 Shetty S, Pendurthi UR, Halady PK, Azghani AO, Idell S. Urokinase induces its own expression in Beas2B lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002; 283 (2) L319-L328
    PubMedGoogle Scholar
  • 48 Shetty S, Bdeir K, Cines DB, Idell S. Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem 2003; 278 (20) 18124-18131
    CrossrefPubMedGoogle Scholar
  • 49 Shetty S, Idell S. New Perspectives on the Regulation of Fibrinolysis in the Lung. Recent Research Developments in Biological Chemistry. 1st ed. Kerela, India: Research Signpost; 2002: 223-230
    Google Scholar
  • 50 Shetty S, Gyetko MR, Mazar AP. Induction of p53 by urokinase in lung epithelial cells. J Biol Chem 2005; 280 (30) 28133-28141
    CrossrefPubMedGoogle Scholar
  • 51 Shetty S, Padijnayayveetil J, Tucker T, Stankowska D, Idell S. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. Am J Physiol Lung Cell Mol Physiol 2008; 295 (6) L967-L975
    CrossrefPubMedGoogle Scholar
  • 52 Shetty S, Idell S. Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro. J Biol Chem 2000; 275 (18) 13771-13779
    CrossrefPubMedGoogle Scholar
  • 53 Shetty S, Idell S. Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro. Mol Cell Biochem 1999; 199 (1–2) 189-200
    CrossrefPubMedGoogle Scholar
  • 54 Shetty S, Idell S. Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. Am J Physiol Lung Cell Mol Physiol 2000; 278 (1) L148-L156
    PubMedGoogle Scholar
  • 55 Shetty S, Velusamy T, Idell S , et al. Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA. Mol Cell Biol 2007; 27 (16) 5607-5618
    CrossrefPubMedGoogle Scholar
  • 56 Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP, Shetty RS. Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem 2008; 283 (28) 19570-19580
    CrossrefPubMedGoogle Scholar
  • 57 Bhandary YP, Shetty SK, Marudamuthu AS , et al. Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. Am J Physiol Lung Cell Mol Physiol 2012; 302 (5) L463-L473
    CrossrefPubMedGoogle Scholar
  • 58 Shetty S, Bhandary YP, Shetty SK , et al. Induction of tissue factor by urokinase in lung epithelial cells and in the lungs. Am J Respir Crit Care Med 2010; 181 (12) 1355-1366
    CrossrefPubMedGoogle Scholar
  • 59 Mubarak KK, Montes-Worboys A, Regev D , et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J 2012; 39 (1) 133-140
    CrossrefPubMedGoogle Scholar
  • 60 Decologne N, Kolb M, Margetts PJ , et al. TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J Immunol 2007; 179 (9) 6043-6051
    PubMedGoogle Scholar
  • 61 Nasreen N, Mohammed KA, Mubarak KK , et al. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am J Physiol Lung Cell Mol Physiol 2009; 297 (1) L115-L124
    CrossrefPubMedGoogle Scholar
  • 62 Tucker TA, Williams L, Koenig K , et al. Lipoprotein receptor-related protein 1 regulates collagen 1 expression, proteolysis, and migration in human pleural mesothelial cells. Am J Respir Cell Mol Biol 2012; 46 (2) 196-206
    CrossrefPubMedGoogle Scholar
  • 63 Olman MA, Hagood JS, Simmons WL, Fuller GM, Vinson C, White KE. Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element. Blood 1999; 94 (6) 2029-2038
    PubMedGoogle Scholar
  • 64 Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285 (1) L20-L28
    CrossrefPubMedGoogle Scholar
  • 65 Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96 (3) 1621-1630
    CrossrefPubMedGoogle Scholar
  • 66 Olman MA, Hagood JS, Simmons WL, White KE. Fibrin fragment response elements in the plasminogen activator inhibitor gene. Chest 1999; 116 (1, Suppl) 118S-119S
    CrossrefPubMedGoogle Scholar
  • 67 Courey AJ, Horowitz JC, Kim KK , et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 2011; 118 (8) 2313-2321
    CrossrefPubMedGoogle Scholar
  • 68 Sisson TH, Simon RH. The plasminogen activation system in lung disease. Curr Drug Targets 2007; 8 (9) 1016-1029
    CrossrefPubMedGoogle Scholar
  • 69 Eitzman DT, Fay WP, Lawrence DA , et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95 (5) 2416-2420
    CrossrefPubMedGoogle Scholar
  • 70 Philip-Joët F, Alessi MC, Philip-Joët C , et al. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 1995; 8 (8) 1352-1356
    CrossrefPubMedGoogle Scholar
  • 71 Chung CL, Chen CH, Sheu JR, Chen YC, Chang SC. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates. Chest 2005; 128 (2) 690-697
    CrossrefPubMedGoogle Scholar
  • 72 Iglesias D, Alegre J, Alemán C , et al. Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J 2005; 25 (1) 104-109
    CrossrefPubMedGoogle Scholar
  • 73 Idell S, Jun Na M, Liao H , et al. Single-chain urokinase in empyema induced by Pasturella multocida. Exp Lung Res 2009; 35 (8) 665-681
    CrossrefPubMedGoogle Scholar
  • 74 Phua J, Badia JR, Adhikari NK , et al. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med 2009; 179 (3) 220-227
    CrossrefPubMedGoogle Scholar
  • 75 Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35 (8) 1821-1828
    CrossrefPubMedGoogle Scholar
  • 76 Günther A, Mosavi P, Heinemann S , et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161 (2 Pt 1) 454-462
    CrossrefPubMedGoogle Scholar
  • 77 Wilberding JA, Ploplis VA, McLennan L , et al. Development of pulmonary fibrosis in fibrinogen-deficient mice. Ann N Y Acad Sci 2001; 936: 542-548
    PubMedGoogle Scholar
  • 78 Günther A, Lübke N, Ermert M , et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168 (11) 1358-1365
    CrossrefPubMedGoogle Scholar
  • 79 Enkhbaatar P, Murakami K, Cox R , et al. Aerosolized tissue plasminogen inhibitor improves pulmonary function in sheep with burn and smoke inhalation. Shock 2004; 22 (1) 70-75
    CrossrefPubMedGoogle Scholar
  • 80 Münster AM, Rasmussen L, Sidelmann J, Ingemann Jensen J, Bech B, Gram J. Effects of inhaled plasminogen activator on the balance between coagulation and fibrinolysis in traumatized pigs. Blood Coagul Fibrinolysis 2002; 13 (7) 591-601
    CrossrefPubMedGoogle Scholar
  • 81 Wagers SS, Norton RJ, Rinaldi LM, Bates JH, Sobel BE, Irvin CG. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest 2004; 114 (1) 104-111
    CrossrefPubMedGoogle Scholar
  • 82 Hardaway RM, Harke H, Williams CH. Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome. Adv Ther 1994; 11 (2) 43-51
    PubMedGoogle Scholar
  • 83 Münster AM, Bendstrup E, Jensen JI, Gram J. Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA). J Aerosol Med 2000; 13 (4) 325-333
    CrossrefPubMedGoogle Scholar
  • 84 Nassar T, Yarovoi S, Fanne RA , et al. Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1. Am J Respir Cell Mol Biol 2010; 43 (6) 703-711
    CrossrefPubMedGoogle Scholar
  • 85 Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18 (1) 1-6
    CrossrefPubMedGoogle Scholar
  • 86 Lackowski NP, Pitzer JE, Tobias M , et al. Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice. Pulm Pharmacol Ther 2010; 23 (2) 107-114
    CrossrefPubMedGoogle Scholar
  • 87 Abraham E, Gyetko MR, Kuhn K , et al. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003; 170 (11) 5644-5651
    PubMedGoogle Scholar
  • 88 Tillett WS, Sherry S, Read CT. The use of streptokinase-streptodornase in the treatment of postneumonic empyema. J Thorac Surg 1951; 21 (3) 275-297
    PubMedGoogle Scholar
  • 89 Idell S. Update on the use of fibrinolysins in pleural disease. Clin Pulm Med 2005; 12 (3) 184-190
    CrossrefPubMedGoogle Scholar
  • 90 Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2008; (2) CD002312
    PubMedGoogle Scholar
  • 91 Maskell NA, Davies CW, Nunn AJ , et al; First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352 (9) 865-874
    CrossrefPubMedGoogle Scholar
  • 92 Sonnappa S, Cohen G, Owens CM , et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174 (2) 221-227
    CrossrefPubMedGoogle Scholar
  • 93 Rahman NM, Maskell NA, West A , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365 (6) 518-526
    CrossrefPubMedGoogle Scholar
  • 94 Huggins JT, Doelken P, Sahn SA. Intrapleural therapy. Respirology 2011; 16 (6) 891-899
    CrossrefPubMedGoogle Scholar
  • 95 Stefanutti G, Ghirardo V, Barbato A, Gamba P. Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: a prospective study. Surgery 2010; 148 (3) 589-594
    CrossrefPubMedGoogle Scholar
  • 96 Thommi G, Shehan JC, Robison KL, Christensen M, Backemeyer LA, McLeay MT. A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respir Med 2012; 106 (5) 716-723
    CrossrefPubMedGoogle Scholar
  • 97 Okur E, Baysungur V, Tezel C, Ergene G, Okur HK, Halezeroglu S. Streptokinase for malignant pleural effusions: a randomized controlled study. Asian Cardiovasc Thorac Ann 2011; 19 (3–4) 238-243
    CrossrefPubMedGoogle Scholar
  • 98 Komissarov AA, Florova G, Idell S. Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem 2011; 286 (49) 41949-41962
    CrossrefPubMedGoogle Scholar
  • 99 Komissarov AA, Mazar AP, Koenig K, Kurdowska AK, Idell S. Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2009; 297 (4) L568-L577
    CrossrefPubMedGoogle Scholar